Swedish Olink technological innovation allows further advancement of South African exploration and innovation

UPPSALA, Sweden, March 29, 2023 (Globe NEWSWIRE) — Olink Holding AB (publ) (Nasdaq: OLK) these days announced that the regional proteomic facility, D-CYPHR in Cape Town, South Africa has adopted Olink know-how and has grow to be the initial service provider utilizing the Olink^® Goal and Olink^® Flex platforms for qualified protein biomarker discovery on the African continent.

D-CYPHR is a new facility co-started by the Centre for Proteomic and Genomic Research (CPGR) and the Institute of Infectious Disease and Molecular Medicine (IDM) less than the DIPLOMICS community programme, an initiative by the South African Department of Science and Innovation (DSI). D-CYPHR enables entry to proteomics and metabolomics platforms and information, supporting sophisticated medical and organic investigate not doable elsewhere in this area.

“One of the targets of the DIPLOMICS programme is to enable and increase accessibility to cutting-edge ‘omics systems and abilities. By means of the D-CYPHR laboratory, we are psyched about the introduction of the Olink know-how, which will dramatically make improvements to the top quality and throughput of innovative proteomics research in South Africa,” mentioned Dr Tim Newman, Plan Supervisor for DIPLOMICS.

Amid the first tasks to advantage from Olink technological know-how will be people directed towards COVID-19 and tuberculosis investigate. The Olink panels for targeted protein biomarker discovery help speedier, superior-informed conclusions in human protein biomarker study by furnishing substantial-multiplex immunoassays advantages without having compromising information top quality or performance.

“The potential to quantify huge panels of secreted and mobile area antigens in medical samples from tuberculosis individuals employing higher throughput, multiplexed Olink assays will permit new insights into immunopathogenesis in this essential infectious disorder,” commented Professor Jonathan Blackburn, Deputy Director of the IDM.

“This is an fascinating chance to develop significant examination of improvements in proteomic profiles and their connected impacts. These analyses will assist elucidate mechanisms fundamental how different illnesses impression individuals with differing levels of severity. This has tremendous implications for circumstances that impact individuals of African descent. Eventually, our operate applying samples from African populations, has the potential to considerably boost wellness results in Africa. We are thrilled to offer our clients with entry to this platform and as a result critical answers to some of their critical investigate thoughts and hope to extend this service to the Olink^® Investigate system in the foreseeable future,” stated Dr Liam Bell, Supervisor of the D-CYPHR proteomic facility.

Story carries on

“Olink is immensely happy to see our technologies contributing to the excellent investigate attempts in South Africa. We know that our technologies will additional stimulate the improvement of groundbreaking science, improving the well-getting of people close to the globe,” stated Jon Heimer, CEO of Olink. “This is an thrilling 1st phase in what I’m confident will be a fruitful and collaborative journey.”

Investor speak to
Jan Medina, CFA
VP Investor Relations & Capital Marketplaces
Mobile: +1 617 802 4157
jan.medina@olink.com

Media call
Andrea Prander
Corporate Communications Supervisor
Mobile: +46 768 775 275
andrea.prander@olink.com

About Olink
Olink Holding AB (Nasdaq: OLK) is a firm devoted to accelerating proteomics alongside one another with the scientific local community, across multiple disease places to help new discoveries and increase the life of individuals. Olink offers a system of products and products and services which are deployed across main pharmaceutical firms and foremost medical and tutorial institutions to deepen the comprehension of genuine-time human biology and push 21st century health care by way of actionable and impactful science. The Firm was launched in 2016 and is very well proven throughout Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.

About DIPLOMICS
DIPLOMICS (Distributed System in OMICS) is one of 13 Analysis Infrastructures proven by the Office of Science and Innovation (DSI) by its South African Research Infrastructure Roadmap (SARIR).

Forward-looking statements
This launch may well contain forward-wanting statements in just the that means of relevant securities rules, which includes the U.S. Private Securities Litigation Reform Act of 1995, as amended, like, without having limitation, statements relating to Olink’s tactic, business enterprise programs and concentration. The words and phrases “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and comparable expressions are supposed to establish ahead-wanting statements, while not all ahead-hunting statements contain these identifying words. Any forward-searching statements in this press release are based on management’s latest expectations and beliefs as of the date hereof and are subject matter to a range of risks, uncertainties and vital factors that may trigger real situations or success to vary materially from those people expressed or implied by any forward-looking statements contained in this press release, which includes, with no limitation, individuals relevant to Olink’s company, functions, provide chain, approach, objectives and expected timelines, together with for the shipping and delivery of Olink Investigate 3072 and the enlargement of the Take a look at system, competitors, and other pitfalls identified in the part entitled “Risk Factors” in Olink’s Registration Assertion on Kind F-1, as amended (File No. 333-253818) submitted with the U.S. Securities and Exchange Commission (SEC) and in the other filings, studies, and files Olink information with the SEC from time to time. Olink expressly disclaims any obligation to update any forward-hunting statements in this launch to reflect any alter in its expectations with regard thereto or any transform in functions, circumstances or conditions on which any these kinds of assertion is based, until expected by law or regulation.